Gilead Sciences: Yeztugo And Trodelvy Make This A Buy Once More
Summary
Gilead Sciences is upgraded to 'Buy' as YEZTUGO's FDA approval strengthens its dominant HIV franchise and long-term outl...
Gilead Sciences is upgraded to 'Buy' as YEZTUGO's FDA approval strengthens its dominant HIV franchise and long-term outlook. GILD's valuation remains attractive, with a P/E of 14.74 and significant upside if revenue growth improves to low-to-mid single digits. While Cell Therapy and Liver Disease portfolios face headwinds, TRODELVY's expansion and LIVDELZI's launch offer meaningful optionality.